Optometry News

Eluminex Biosciences has dosed the first patient in the phase 1b LOTUS trial, which will evaluate three dose levels of the trispecific fusion antibody EB-105 in patients with diabetic macular edema.

In a paper recently published in Retina, an expert panel of retina specialists provided guidance on suprachoroidal space injection.

Lack of standardization in comfort and safety assessments makes it difficult to compare silicone hydrogel and hydrogel contact lenses, according to a recent review.

The FDA granted 510(k) clearance to the Faros anterior cataract surgery system from Oertli Instrumente, according to a press release.

PARK CITY, Utah — Suprachoroidal drug delivery for uveitic macular edema provides durable effects in real-world settings, matching those of phase 3 clinical trials, according to a speaker at Clinical Trials at the Summit.

Astigmatic contact lens wear poses two key challenges: comfort and stability of vision.

The first analysis of real-world outcomes in patients with neovascular age-related macular degeneration treated with pegcetacoplan for geographic atrophy demonstrated similar safety seen in clinical trials, according to a study.

PARK CITY, Utah — APX3330, an investigational systemic treatment for diabetic retinopathy, showed encouraging outcomes in the phase 2 ZETA-1 trial, paving the way to phase 3.

Eyenovia and Senju Pharmaceutical Co. have announced a collaboration agreement to develop Senju’s SJP-0035 for use with Eyenovia’s Optejet dispensing technology as a combination product to treat chronic dry eye disease.

Pars plana vitrectomy with internal limiting membrane peeling for macular hole closure is better than pars plana vitrectomy without internal limiting membrane peeling, according to a study.